---
title: A study to find out how healthy people tolerate a new drug called S221237.
euct_id: 2024-519381-53-00
eudra_ct_number: 2022-001526-30
phase: Phase 1
status: Completed
sponsor: Institut De Recherches Internationales Servier IRIS
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-519381-53-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-519381-53-00"
ctis_last_updated: "2025-09-23T03:30:46.771983578"
source: EU Clinical Trials Information System (CTIS)
---
# A study to find out how healthy people tolerate a new drug called S221237.

**EU CT Number:** [2024-519381-53-00](https://euclinicaltrials.eu/ctis-public/view/2024-519381-53-00)

## Key Facts

- **Phase:** Phase 1
- **Status:** Completed
- **Sponsor:** Institut De Recherches Internationales Servier IRIS
- **Start Date:** 2022-09-01
- **Completion Date:** 2025-05-30
- **Conditions:** Parkinson disease (PD), Parkinson's disease, Nervous system disorders

## Member States

Trial is authorized in 1 member state: France.

## Sites (1)

- Eurofins Optimed, Gieres, France

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson disease (PD); Parkinson's disease; Nervous system disorders
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-519381-53-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-519381-53-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-519381-53-00*